GlaxoSmithKline now says it will wait for the completion of a late-stage trial of its cervical cancer vaccine Cervarix before answering the FDA's questions about the therapy. That will push back any approval of Cervarix until 2010, at the earliest. And it confirms some of the worst fears of market analysts, who see Merck's Gardasil gobbling up the market long before Cervarix arrives on the scene.
The long-term efficacy trial that GSK is waiting on tracks the real-world experiences of girls and young women who have been vaccinated. The cancer vaccine is on sale in 67 countries.
- read the report in the Financial Times